SLS Bio: Q1 2026 Operating Loss of KRW 950M, Under Listing Eligibility Review

Q1 2026 sales KRW 957.7M, operating loss KRW 950.4M, net loss KRW 938.7M (vs net loss KRW 198.7M in Q1 2025, loss widened)
Operating cash flow negative KRW 815.8M (vs positive KRW 191.7M in Q1 2025)
Debt ratio increased to 50.6% from 47.1% at end of 2025
Under listing eligibility review by Korea Exchange with improvement period until Aug 31, 2026
Designated as unfaithful disclosure corporation in Dec 2025 (3 penalty points)
No dividends or share buybacks